These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 15477297)

  • 1. Hereditary cancer: guidelines in clinical practice. Breast and ovarian cancer genetics.
    Eccles DM
    Ann Oncol; 2004; 15 Suppl 4():iv133-8. PubMed ID: 15477297
    [No Abstract]   [Full Text] [Related]  

  • 2. Hereditary breast-ovarian cancer: clinical findings and medical management.
    Marshall M; Solomon S
    Plast Surg Nurs; 2007; 27(3):124-7. PubMed ID: 17901820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic testing for hereditary breast and ovarian cancer and the USPSTF recommendations.
    Wood ME; Garber JE; Isaacs C; Masood S; Bedrosian I; Tung N; Chun J; Schnabel FR; Arun BK;
    Breast J; 2019 Jul; 25(4):575-577. PubMed ID: 31280501
    [No Abstract]   [Full Text] [Related]  

  • 4. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes.
    Berry DA; Iversen ES; Gudbjartsson DF; Hiller EH; Garber JE; Peshkin BN; Lerman C; Watson P; Lynch HT; Hilsenbeck SG; Rubinstein WS; Hughes KS; Parmigiani G
    J Clin Oncol; 2002 Jun; 20(11):2701-12. PubMed ID: 12039933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identifying and managing hereditary risk of breast and ovarian cancer.
    Frank TS; Critchfield GC
    Clin Perinatol; 2001 Jun; 28(2):395-406. PubMed ID: 11499060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of cancer at sites other than the breast in Swedish families eligible for BRCA1 or BRCA2 mutation testing.
    Lorenzo Bermejo J; Hemminki K
    Ann Oncol; 2004 Dec; 15(12):1834-41. PubMed ID: 15550590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening for common mutations in BRCA1 and BRCA2 genes: interest in genetic testing of Tunisian families with breast and/or ovarian cancer.
    Fourati A; Louchez MM; Fournier J; Gamoudi A; Rahal K; El May MV; El May A; Revillion F; Peyrat JP
    Bull Cancer; 2014 Nov; 101(11):E36-40. PubMed ID: 25418591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical management of women with genomic BRCA1 and BRCA2 mutations.
    Chang J; Elledge RM
    Breast Cancer Res Treat; 2001 Sep; 69(2):101-13. PubMed ID: 11759816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contribution of BRCA2 germline mutations to hereditary breast/ovarian cancer in Germany.
    Hamann U; Liu X; Lange S; Ulmer HU; Benner A; Scott RJ
    J Med Genet; 2002 Mar; 39(3):E12. PubMed ID: 11897832
    [No Abstract]   [Full Text] [Related]  

  • 10. Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening.
    Paluch-Shimon S; Cardoso F; Sessa C; Balmana J; Cardoso MJ; Gilbert F; Senkus E;
    Ann Oncol; 2016 Sep; 27(suppl 5):v103-v110. PubMed ID: 27664246
    [No Abstract]   [Full Text] [Related]  

  • 11. Germline mutations in BRCA1 and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinic.
    Martin AM; Blackwood MA; Antin-Ozerkis D; Shih HA; Calzone K; Colligon TA; Seal S; Collins N; Stratton MR; Weber BL; Nathanson KL
    J Clin Oncol; 2001 Apr; 19(8):2247-53. PubMed ID: 11304778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic risk assessment and BRCA mutation testing.
    Ormond KE; Bellcross C; Weissman S
    Ann Intern Med; 2006 Feb; 144(4):303-4; discussion 304. PubMed ID: 16490919
    [No Abstract]   [Full Text] [Related]  

  • 13. Genetic testing and interpretive complexity: a BRCA1 gene mutation example.
    Gogarty DS; Farrell MP; Gallagher DJ
    Ir J Med Sci; 2016 Nov; 185(4):955-957. PubMed ID: 25503966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phenotypic expression of double heterozygosity for BRCA1 and BRCA2 germline mutations.
    Leegte B; van der Hout AH; Deffenbaugh AM; Bakker MK; Mulder IM; ten Berge A; Leenders EP; Wesseling J; de Hullu J; Hoogerbrugge N; Ligtenberg MJ; Ardern-Jones A; Bancroft E; Salmon A; Barwell J; Eeles R; Oosterwijk JC
    J Med Genet; 2005 Mar; 42(3):e20. PubMed ID: 15744030
    [No Abstract]   [Full Text] [Related]  

  • 15. Counseling the at risk patient in the BRCA1 and BRCA2 Era.
    Barnes-Kedar IM; Plon SE
    Obstet Gynecol Clin North Am; 2002 Jun; 29(2):341-66, vii. PubMed ID: 12108833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRCA1 and BRCA2: to test or not to test.
    Brandt RT; Lynch HT
    Breast Cancer Res Treat; 2001 May; 67(2):187-8. PubMed ID: 11519868
    [No Abstract]   [Full Text] [Related]  

  • 17. The frequency of cancer predisposition gene mutations in hereditary breast and ovarian cancer patients in Taiwan: From BRCA1/2 to multi-gene panels.
    Sung PL; Wen KC; Chen YJ; Chao TC; Tsai YF; Tseng LM; Qiu JT; Chao KC; Wu HH; Chuang CM; Wang PH; Huang CF
    PLoS One; 2017; 12(9):e0185615. PubMed ID: 28961279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRCA1 and BRCA2 cancer risks.
    Antoniou AC; Pharoah PD; Easton DF; Evans DG
    J Clin Oncol; 2006 Jul; 24(20):3312-3; author reply 3313-4. PubMed ID: 16829658
    [No Abstract]   [Full Text] [Related]  

  • 19. Familial breast and ovarian cancers.
    Arai M; Utsunomiya J; Miki Y
    Int J Clin Oncol; 2004 Aug; 9(4):270-82. PubMed ID: 15375703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical significance of recognizing distinct morphologic and biologic features of hereditary breast cancer.
    Masood S
    Breast J; 2002; 8(2):69. PubMed ID: 11896749
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.